Hodgkin Lymphoma Pathways

<table>
<thead>
<tr>
<th>Patient Name:</th>
<th>Date of Birth:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Member Number:</td>
<td>Treatment Start Date:</td>
</tr>
</tbody>
</table>

**Pathology:** 

**Line of Therapy:**
- __1st Line__ 
- __2nd Line__ 
- __3rd Line__ 
- __3rd Line+__

**ECOG Performance Status:** 

**ICD-10 Code:**

**Biomarkers/Characteristics:** (select all that apply)
- CD20 status: __Negative__ __Positive__
- HIV associated lymphoma: __No__ __Yes__
- Transplant Candidate: __No__ __Yes__

### Classical Hodgkin Lymphoma | Early Stage (Stage I-IIA, Favorable and Unfavorable Risk)

___ABVD: doxorubicin (Adriamycin), bleomycin, vinblastine, and dacarbazine (DTIC) ± ISRT*

### Classical Hodgkin Lymphoma | Advanced Stage (Stage IIB, III, and IV)

___ABVD: doxorubicin (Adriamycin), bleomycin, vinblastine, and dacarbazine (DTIC) ± ISRT*

*ISRT – Involved site radiation therapy

**Note:** Pathways are independent of specific health plan medical policy coverage criteria. Health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered. Biosimilars or alternate formulations (along with the reference products) are considered on pathway unless otherwise specified by health plan formularies, medical policies, or preferred product rules.